Krones, Elisabeth
Marschall, Hanns-Ulrich
Fickert, Peter
Funding for this research was provided by:
Medical University of Graz
Article History
First Online: 13 February 2019
Compliance with Ethical Standards
:
: Elisabeth Krones: received an unrestricted research grant and norUDCA from Dr. Falk Pharma GmbH, Freiburg, GermanyHanns-Ulrich Marschall: Consulting for Albireo, Bayer, Intercept; research grant of Intercept, material support by Albireo, InterceptPeter Fickert: The Medical University of Graz has filed <i>nor</i>UDCA patents for the treatment of liver diseases and arteriosclerosis and P.F. is co-inventor (WO2006119803 and WO20099013334); speaker for Falk Foundation, advisory boards for Dr. Falk Pharma GmbH and Intercept; travel grants and unrestricted research grants from Falk Foundation and unrestricted research grant from Gilead Sciences Inc.
: This article does not contain any studies with human or animal subjects performed by any of the authors.